rezafungin

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

REZZAYO — MUNDIPHARMA, approved 2026-07-16 (NDA217417).

Most reported adverse events (US / FAERS)

91 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

off label use

35

product prescribing issue

12

no adverse event

11

drug ineffective

4

Medicines containing this active substance

1 medicines

Rezzayo

Authorised

🇺🇸 Also approved in the US (FDA)

REZZAYO — MUNDIPHARMA, approved 2026-07-16 (NDA217417).

Most reported adverse events (US / FAERS)

91 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

off label use

35

product prescribing issue

12

no adverse event

11

drug ineffective

4

product use issue

4

candida infection

3

death

3

drug ineffective for unapproved indication

3

dyspnoea

3

product dose omission issue

3

covid-19

2

dizziness

2

drug resistance

2

erythema

2

extravasation

2